Warren , R.; Armstrong , A.; Gooderham, M.; Strober , B.; Thaci, D.; Imafuku, S.; Sofen, H.; Spelman, L.; Korman, N.; Zheng, M.; Colston, E.; Throup , J.; Kundu, S.; Kisa, R.; Banerjee, S.; Blauvelt, A. . Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2022, 6, s4.